Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19280962 | 0.89 | CASP3 (0.54) | CASP3EPHX2KMT2APIN1MDM2 | |
| SCHEMBL29415585 | 0.88 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL21731443 | 0.88 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL22283287 | 0.88 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL16285132 | 0.88 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL15482107 | 0.88 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL29352081 | 0.88 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL29677937 | 0.87 | CASP3 (0.52) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL16646584 | 0.87 | CASP3 (0.52) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL20880298 | 0.85 | CASP3 (0.51) | CASP3EPHX2KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702473-B2 | Site-specific antibody-drug conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-18 | — | — | US | disclosed |
| CN-108093640-B | Site-specific antibody-drug conjugates | ADC治疗股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20200399365-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-12-24 | — | — | US | disclosed |
| EP-3054989-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2019-03-27 | — | — | EP | disclosed |
| EP-3054983-B1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3054986-B1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3054985-B1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LTD (GB) | 2018-12-26 | — | — | EP | disclosed |
| US-20180303953-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ADC THERAPEUTICS S.A. (CH) | 2018-10-25 | — | — | US | disclosed |
| US-10017580-B2 | Humanized anti-Tn-MUC1 antibodies and their conjugates | ADC Therpeutics S.A. (CH) | 2018-07-10 | — | — | US | disclosed |
| US-10010624-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2018-07-03 | — | — | US | disclosed |
| EP-3054984-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2016-08-17 | — | — | EP | disclosed |
| EP-3054983-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2016-08-17 | — | — | EP | disclosed |
| EP-3054989-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MedImmune Limited (GB) | 2016-08-17 | — | — | EP | disclosed |
| EP-3054985-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015159076-A1 | HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015052321-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SÀRL (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052534-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | SPIROGEN SÀRL (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052535-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | SPIROGEN SÀRL (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052533-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | SPIROGEN SÀRL (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052532-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | SPIROGEN SÀRL (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399365-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | SBDS, DCTD, DRD1 | CASP3 3788/4885EPHX2 897/4885KMT2A 363/4885 |
| US-20180303953-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ERBB2, SBDS, CD22 | CASP3 3706/4885EPHX2 1716/4885KMT2A 695/4885 |
| US-10010624-B2 | Pyrrolobenzodiazepine-antibody conjugates | PSMA2, PSMA7, PSMA1 | CASP3 3108/4885EPHX2 2219/4885KMT2A 478/4885 |
| US-11702473-B2 | Site-specific antibody-drug conjugates | SBDS, DCTD, DRD1 | CASP3 3788/4885EPHX2 897/4885KMT2A 363/4885 |
| US-10017580-B2 | Humanized anti-Tn-MUC1 antibodies and their conjugates | MUC1, CD44, VIM | CASP3 3278/4885EPHX2 4176/4885KMT2A 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.